

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request: cder\_iqp\_wp036

**Request ID:** cder\_iqp\_wp036

**Request Description:** In this report we aimed to provide counts of users of 51 new molecular entities (NMEs), stratified by year, that were approved by the FDA in 2021 in the TriNetX Live™ platform.

**Data Source:** We ran this query on February 13, 2024. This query contains data from 59 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network with Minimal Shift from December 18, 2020 to December 31, 2023.

TriNetX aggregates electronic health record (EHR) systems data from its partner HCOs to create queryable datasets. TriNetX datasets primarily comprise clinical patient data such as demographics, diagnoses, procedures, labs, and medications. The USA Network with Minimal Shift contains HCOs that date shift their data by 14 or fewer days (including 0). For more information on the TriNetX Live™ platform and the TriNetX data visit their website here: <https://trinetx.com/>

**Study Design:** In this retrospective cohort study, we identified counts of individuals with evidence of exposure to the 51 approved NMEs, stratified by year (2021 to 2023). We built 171 distinct cohorts (57 for each year) using the Query Builder module in the TriNetX Live™ platform.

**Exposures of Interest:** We examined 51 NMEs of interest. These included: aducanumab-avwa, amivantamab-vmjw, anifrolumab-fnia, asciminib, asparaginase erwinia chrysanthemi (recombinant)-rywn, atogepant, avacopan, avalglucosidase alfa-ngpt, belumosudil, belzutifan, cabotegravir, cabotegravir and rilpivirine (co-packaged injectable route only), casimersen, dasiglucagon, difelikefalin, dostarlimab-gxly, drospirenone and estetrol, efgartigimod alfa-fcab, evinacumab-dgnb, fexinidazole, finerenone, fosdenopterin, ibrexafungerp, inclisiran, infigratinib, loncastuximab tesirine-lpyl, lonapegsomatropin-tcgd, maralixibat, maribavir, melphalan flufenamide, mobocertinib, odevixibat, olanzapine and samidorphan, pafolacianine, pegcetacoplan, piflufolastat F-18, ponesimod, ropeginterferon alfa-2b-njft, serdexmethylphenidate and dexmethylphenidate, sotorasib, tepotinib, tezepelumab-ekko, tisotumab vedotin-tftv, tivozanib, tralokinumab-ldrm, trilaciclib, umbralisib, vericiguat, viloxazine, voclosporin, and vosoritide.

We used RxNorm medication terms and Healthcare Common Procedure Coding System (HCPCS) procedure codes in the Query Builder module. In order to be included in each of the yearly cohort, we required evidence of a prescription, administration, or dispensing with the relevant NME of interest (with or without additional filters) within the following query periods:

- 1) December 18, 2020 to December 17, 2021 for the 2021 cohort.
- 2) December 18, 2021 to December 17, 2022 for the 2022 cohort.
- 3) December 18, 2022 to December 31, 2023 for the 2023 cohort.

### Overview for Request: cder\_iqp\_wp036

**Sensitivity Analyses:** For certain NME exposures which have non-specific RxNorm medication terms or that are part of co-packaged NMEs, we used filters for brand names or route of administration in the TriNetX platform to more accurately identify exposures. To this end, we included additional cohorts to compare patient counts with and without the filters. We included the following sensitivity tests:

- \* Asparaginase erwinia chrysanthemi (recombinant)-rywn: with and without brand name, Rylaze
- \* Cabotegravir alone: overall, oral route only, injectable route only, and brand name of Apretude or Vocabria. For the overall and oral route only cohorts, we additionally excluded patients with same-day exposures of rilpivirine.
- \* Efgartigimod alfa-fcab: with and without brand name, Vyvgart
- \* Pegcetacoplan: with and without brand name, Empaveli

**Note:** In the present query, we have three fixed dose combination NMEs, for which at least one individual drug is available only as part of the combination (estetrol from drospirinone + estetrol, samidorphan from olanzapine + samidorphan and serdexmethylphenidate from dexamethylphenidate + serdexmethylphenidate). Because of this, we did not require any brand filters as part of sensitivity analyses. We assumed that any prescription/dispensing of the three individual drugs (estetrol, samidorphan and serdexmethylphenidate) would reflect the combination NME itself.

**Please see Appendix A for the list of RxNorm medication terms and HCPCS procedure codes, with information on filters used to define the exposures of interest in this request.**

**Cohort Eligibility Criteria:** We created separate 2021, 2022 and 2023 cohorts for each of the 51 NMEs with additional sensitivity cohorts with the query periods as detailed in the "Exposures of Interest" section (total 171 cohorts; 57 cohorts for each year). Patients of all ages were included in all the cohorts.

**Please see Appendix B for the specifications of the cohort parameters for each of the 171 cohorts as included in the Query Builder.**

**Limitations:** Algorithms used to define exposures, characteristics, and pregnancy, and mapping of source data to the data model are imperfect and susceptible to misclassification. Additionally, EHR data in the U.S. lacks longitudinality. The information before or after patients' healthcare encounters could be missing, especially if patient care was administered across different HCOs that may or might not participate in the TriNetX USA network. We are unable to determine if absence of evidence of a condition implies a true absence of a condition or if the condition was not observed in the data. Furthermore, not all HCOs provide brand name or route information for RxNorm terms or laboratory data. Therefore, data should be interpreted with these limitations in mind.

All counts provided through the TriNetX Live™ platform are rounded up to the nearest 10 to protect patient privacy. This rounding affects error, especially as sample sizes decrease. Error due to rounding can range from <0.09% when sample sizes are >10,000 to nearly 20% as sample sizes drop. Thus, all estimates should be interpreted as ranges, and small sample sizes should be interpreted with caution. Additionally, percentages are calculated based on these rounded numerators and denominators. Thus, due to rounding, the sum of each value in a category may not total to 100%.

### Overview for Request: cder\_iqp\_wp036

The TriNetX Live™ platform uses RxNorm terms to identify medications, specifically the primary ingredient RxNorm terms.

- Generally, in case of fixed dose combinations/co-packaged medications, the drugs can be identified in the platform as the presence of primary ingredient RxNorm terms for all the individual medications on the same day (even if a multiple ingredient RxNorm term is made available by the National Library of Medicine), under the assumption that this refers only to the combined drugs and not two individual drugs prescribed concomitantly. We can have exposure misclassification if the assumption does not hold.

In the present query, we created the cohorts for a co-packaged NME (cabotegravir with rilpivirine) with both individual drugs (with the filter specifying injectable route) required to be prescribed/dispensed on the same day.

- Additionally, the RxNorm terms for certain NMEs in the query were non-specific (i.e., referred to more than one drug in the market). For example, the primary ingredient RxNorm term for Asparaginase erwinia chrysanthemi (recombinant)-rywn (brand Rylaze, approved in 2021) is the same as for Asparaginase erwinia chrysanthemi (brand Erwinaze, approved in 2011). To investigate such instances further, we have created sensitivity analyses cohorts with and without the brand name filter.

**Notes:** We ran this query on February 13, 2024. A re-run of this query for the same query period in the future may not yield the same results owing to the dynamic nature of the TriNetX Live™ network.

Please contact the Sentinel Operations Center ([info@sentinelssystem.org](mailto:info@sentinelssystem.org)) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's querying in the TriNetX platform, please refer to the Sentinel Website (<https://www.sentinelinitiative.org/methods-data-tools/methods/trinetx-rapid-querying>).

<b>Table of Contents</b>	
<b>Glossary</b>	Glossary of Terms for Analyses Using TriNetX Live™ Platform
<b>Table 1</b>	Counts of Users of New Molecular Entities (NMEs) Approved in 2021 in the TriNetX Minimal Shift USA Network from December 18, 2020 through December 31, 2023, by Year
<b>Appendix A</b>	List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request
<b>Appendix B</b>	Specifications Defining Query Builder Modules in this Request

### Glossary of Terms for Analyses Using TriNetX Live™ Platform\*

- Characteristic** - A medical fact (e.g., diagnosis, procedure, lab result) that occurred on or before the cohort-defining index event.
- Explore Cohort** - A description module on the TriNetX platform that presents a clinical profile of patients in a given cohort. Patient counts are rounded up to the nearest 10 before percentages are calculated, so the sum each of the values in one category may not total to 100%.
- Date Shifting** - A data obfuscation technique that some HCOs use to preserve patient privacy. Date shifting entails assigning each patient a random number of days (eg, -365 to +365 days) and consistently adjusting each of their dates by that number of days, thus maintaining temporal relationships between records within a single patient.
- Fact** - (Medical Fact) A unit of utilization that represents a medical observation on a patient (e.g., diagnosis, procedure, clinical observation).
- Filter** - A method of limiting terms included in queries to a specific subset of data. Filters include age at time of event, data source (electronic health record or natural language processing); brand name, route, and strength for medication terms; occurrence (first or most recent) for lab terms; and priority for diagnosis and procedure terms.
- Group** - A series of codes and terms defined with Boolean logic that are used to create a query cohort. For each group, users have the ability to specified time periods of interest, and the number of instances that the group must occur for cohort entry.
- Subgroup** - Within a group, additional subgroups can be specified to define temporal relationships between the terms in the subgroup (e.g., terms in subgroup B must occur within 5 days after terms in subgroup A). Users can require that these temporal constraints be applied to the 1) first, 2) last, or 3) any instance of each subgroup.
- Health Care Organization (HCO)** - Organizations that contribute electronic healthcare record data to the TriNetX data networks. HCOs include academic institutions and community health provider systems and a single HCO may contain one or more individual sites or facilities.
- Index** - The first date when a patient meets all of the cohort-defining criteria. In Analytics modules, the index can be defined as the date when a patient meets all of the cohort criteria, or only one specific group's criteria.
- Module** - A subsection of the TriNetX platform that performs a distinct functionality. Cohorts are created using the Query Builder module. Descriptive modules include Healthcare Organizations, Explore Cohorts, Rate of Arrival, Summary Statistics, and Analyze Criteria. Advanced analytic modules include Analyze Outcomes, Compare Outcomes, Compare Cohorts, Treatment Pathways, and Incidence and Prevalence.
- Network** - An aggregation of HCOs contributing data to the platform. Multiple networks are available for querying on the platform; the different networks represent subsets of HCOs organized by date-shifting practices or availability of downloadable datasets.
- Outcome** - A medical fact (e.g., diagnosis, procedure, lab result) that occurred on or after the cohort-defining index event.
- Query** - In the TriNetX platform, a query is a distinct cohort with a unique set of terms and logic. Query cohorts are created using the Query Builder platform module.
- Risk** - In Advanced Analytics modules, risk refers to the percentage of patients in each cohort with the specified outcome of interest.
- Priority** - An indication whether the code was the condition that the provider spent the most time evaluating or treating during a visit. Possible values include primary, secondary, or unknown.
- Term** - The codes used to specify patient cohort criteria in a query. Code options include diagnoses, procedures, medications, labs, demographics, genomics, and visits. Terms can be linked together using and/or Boolean logic. TriNetX also creates terms that group together multiple medical codes into single clinical concepts.
- Cannot Have Term** - A category of terms within a query group that patients must not have evidence of to be included in the cohort.
- Must Have Term** - A category of terms within a query group that patients must have evidence of to be included in the cohort.
- Time Constraint** - used to define time periods of interest for each group within a query. Time constraints can be defined relative to the date the query was run (e.g., any time before today), or defined based on specific dates (e.g., January 1, 2015 to September 30, 2020).
- Treatment Pathway** - In Advanced Analytics modules, the Treatment Pathways module returns the order in which patients received treatment and the prevalence of treatments, including combination of medications, following an index event.
- TriNetX Codes** - For commonly used laboratory terms, TriNetX aggregates Logical Observation Identifiers Names and Codes (LOINC) laboratory codes at a clinically significant level to new queryable TNX:LAB terms.

**Visit** - A type of term used to specify the type of medical encounter or facility where the encounter was recorded. Visit terms are derived by TriNetX from the source data. Visits are recorded separately from the codes or labs that occurred during the encounter; care settings are not attached to individual codes. Values for visit terms include: ambulatory, emergency, field, home health, inpatient encounter, inpatient acute, inpatient non-acute, laboratory, observation, pharmacy, pre-admission, short stay, virtual, and unknown.

\*all terms may not be used in this report

**Table 1. Counts of Users of New Molecular Entities (NMEs) Approved in 2021 in the TriNetX Minimal Shift USA Network from December 18, 2020 through December 31, 2023, by Year**

New Molecular Entity	2021	2022	2023
Aducanumab-avwa	50	30	110
Anifrolumab-fnia	20	260	520
Asciminib	30	230	350
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn	230	250	300
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn: Brand - Rylaze	20	110	160
Atogepant	480	7,410	12,020
Avacopan	10	130	180
Avalglucosidase Alfa-ngpt	20	50	60
Belumosudil	200	370	360
Belzutifan	40	160	200
Cabotegravir: Overall	10	530	1,100
Cabotegravir: Route - Oral	410	600	330
Cabotegravir: Route - Injectable	10	490	940
Cabotegravir: Brand - Apretude or Vocabria	230	400	390
Cabotegravir and Rilpivirine: Route - Injectable	480	1,850	2,480
Casimersen	20	30	20
Dasiglucagon	100	350	490
Difelikefalin	0	10	20
Dostarlimab-gxly	40	60	140
Drospirenone and Estetrol	130	650	990
Efgartigimod Alfa-fcab	0	210	250
Efgartigimod Alfa-fcab: Brand - Vyvgart	0	90	90
Evinacumab-dgnb	10	20	20
Fexinidazole	0	0	0
Finerenone	130	1,460	2,660
Fosdenopterin	10	10	10
Ibrexafungerp	170	670	610
Inclisiran	0	700	1,790
Infigratinib	10	20	10
Loncastuximab Tesirine-lpyl	50	60	40
Lonapegsomatropin-tcgd	10	270	630
Maralixibat	10	50	60
Maribavir	10	200	270
Melphalan Flufenamide	60	10	10
Mobocertinib	20	40	30
Odevixibat	10	30	40
Olanzapine and Samidorphan	20	350	490
Pafolacianine	0	0	0
Pegcetacoplan	20	30	150
Pegcetacoplan: Brand - Empaveli	10	10	20
Piflufolostat F-18	210	5,290	7,000
Ponesimod	20	70	60
Ropeginterferon Alfa-2b-njft	0	250	270
Serdexmethylphenidate and Dexmethylphenidate	40	460	2,380
Sotorasib	250	440	330
Tepotinib	20	30	50
Tezepelumab-ekko	0	630	1,210
Tisotumab Vedotin-tftv	20	60	80
Tivozanib	60	130	150
Tralokinumab-ldrm	0	190	420



**Table 1. Counts of Users of New Molecular Entities (NMEs) Approved in 2021 in the TriNetX Minimal Shift USA Network from December 18, 2020 through December 31, 2023, by Year**

<b>New Molecular Entity</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Trilaciclib	20	30	30
Umbralisib	70	40	10
Vericiguat	160	500	800
Viloxazine	530	2,390	4,490
Voclosporin	90	170	190
Vosoritide	0	40	70

**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

Code	Code Type	Description	Filter
<b>Aducanumab-avwa</b>			
J0172	HCPCS	Injection, aducanumab-avwa, 2 mg	
<b>Amivantamab-vmjw</b>			
2549199	RxNorm	Amivantamab	
C9083	HCPCS	Injection, amivantamab-vmjw, 10 mg	
J9061	HCPCS	Injection, amivantamab-vmjw, 2 mg	
<b>Anifrolumab-fnia</b>			
2565265	RxNorm	Anifrolumab	
C9086	HCPCS	Injection, anifrolumab-fnia, 1 mg	
J0491	HCPCS	Injection, anifrolumab-fnia, 1 mg	
<b>Asciminib</b>			
2584304	RxNorm	Asciminib	
<b>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</b>			
1156	RxNorm	Asparaginase	Brand: Rylaze
J9021	HCPCS	Injection, asparaginase, recombinant, (Rylaze), 0.1 mg	
<b>Atogepant</b>			
2571813	RxNorm	Atogepant	
<b>Avacopan</b>			
2572100	RxNorm	Avacopan	
<b>Avalglucosidase Alfa-ngpt</b>			
2565814	RxNorm	Avalglucosidase alfa	
C9085	HCPCS	Injection, avalglucosidase alfa-ngpt, 4 mg	
J0219	HCPCS	Injection, avalglucosidase alfa-ngpt, 4 mg	
<b>Belumosudil</b>			
2564025	RxNorm	Belumosudil	
<b>Belzutifan</b>			
2567226	RxNorm	Belzutifan	
<b>Cabotegravir (Individually)</b>			
2475077	RxNorm	Cabotegravir	Route: Oral, Injectable; Brand: Apretude, Vocabria
J0739	HCPCS	Injection, cabotegravir, 1 mg	
<b>Cabotegravir and Rilpivirine (Co-packaged)</b>			
2475077	RxNorm	Cabotegravir	Route: Injectable
1102270	RxNorm	Rilpivirine	Route: Injectable
C9077	HCPCS	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	
J0741	HCPCS	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	
<b>Casimersen</b>			
2480096	RxNorm	Casimersen	
C9075	HCPCS	Injection, casimersen, 10 mg	
J1426	HCPCS	Injection, casimersen, 10 mg	

**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

Code	Code Type	Description	Filter
<b>Dasiglucagon</b>			
2535233	RxNorm	Dasiglucagon	
<b>Difelikefalin</b>			
2569089	RxNorm	Difelikefalin	
<b>Dostarlimab-gxly</b>			
2539967	RxNorm	Dostarlimab	
C9082	HCPCS	Injection, dostarlimab-gxly, 100 mg	
J9272	HCPCS	Injection, dostarlimab-gxly, 10 mg	
<b>Drospirenone and Estetrol</b>			
11636	RxNorm	Drospirenone	
2539031	RxNorm	Estetrol	
<b>Efgartigimod Alfa-fcab</b>			
2587717	RxNorm	Efgartigimod alfa	Brand: Vyvgart
<b>Evinacumab-dgnb</b>			
2478335	RxNorm	Evinacumab	
C9079	HCPCS	Injection, evinacumab-dgnb, 5 mg	
J1305	HCPCS	Injection, evinacumab-dgnb, 5 mg	
<b>Fexinidazole</b>			
2564146	RxNorm	Fexinidazole	
<b>Finerenone</b>			
2562811	RxNorm	Finerenone	
<b>Fosdenopterin</b>			
2531288	RxNorm	Fosdenopterin	
<b>Ibexafungerp</b>			
2560213	RxNorm	Ibexafungerp	
<b>Inclisiran</b>			
2588243	RxNorm	Inclisiran	
OMOP5051438	RxNorm	Inclisiran	
<b>Infigratinib</b>			
2550729	RxNorm	Infigratinib	
<b>Loncastuximab Tesirine-lpyl</b>			
2540964	RxNorm	Loncastuximab tesirine	
C9084	HCPCS	Injection, loncastuximab tesirine-lpyl, 0.1 mg	
<b>Lonapegsomatropin-tcgd</b>			
2569562	RxNorm	Lonapegsomatropin	
<b>Maralixibat</b>			
2571074	RxNorm	Maralixibat	
<b>Maribavir</b>			
2586068	RxNorm	Maribavir	

**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

Code	Code Type	Description	Filter
<b>Melphalan Flufenamide</b>			
2531369	RxNorm	Melphalan flufenamide	
C9080	HCPCS	Injection, melphalan flufenamide HCl, 1 mg	
J9247	HCPCS	Injection, melphalan flufenamide, 1 mg	
<b>Mobocertinib</b>			
2570736	RxNorm	Mobocertinib	
<b>Odevixibat</b>			
2563966	RxNorm	Odevixibat	
<b>Olanzapine and Samidorphan</b>			
61381	RxNorm	Olanzapine	
2559612	RxNorm	Samidorphan	
<b>Pafolacianine</b>			
2586857	RxNorm	Pafolacianine	
<b>Pegcetacoplan</b>			
2557372	RxNorm	Pegcetacoplan	Brand: Empaveli
<b>Piflufolastat F-18</b>			
2556617	RxNorm	Piflufolastat	
A9595	HCPCS	Piflufolastat F-18, diagnostic, 1 mCi	
<b>Ponesimod</b>			
2532300	RxNorm	Ponesimod	
<b>Ropeginterferon Alfa-2b-njft</b>			
2587059	RxNorm	Ropeginterferon alfa-2b	
<b>Serdexmethylphenidate and Dexmethylphenidate</b>			
2562176	RxNorm	Serdexmethylphenidate	
352372	RxNorm	Dexmethylphenidate	
<b>Sotorasib</b>			
2550714	RxNorm	Sotorasib	
<b>Tepotinib</b>			
2477103	RxNorm	Tepotinib	
<b>Tezepelumab-ekko</b>			
2587789	RxNorm	Tezepelumab	
J2356	HCPCS	Injection, tezepelumab-ekko, 1 mg	
<b>Tisotumab Vedotin-tftv</b>			
2571095	RxNorm	Tisotumab	
OMOP5179229	RxNorm	Tisotumab vedotin	
<b>Tivozanib</b>			
2534233	RxNorm	Tivozanib	

**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

Code	Code Type	Description	Filter
<b>Tralokinumab-ldrm</b>			
2589225	RxNorm	Tralokinumab	
<b>Trilaciclib</b>			
2479690	RxNorm	Trilaciclib	
<b>Umbralisib</b>			
2478439	RxNorm	Umbralisib	
<b>Vericiguat</b>			
2475830	RxNorm	Vericiguat	
<b>Viloxazine</b>			
11196	RxNorm	Viloxazine	
<b>Voclosporin</b>			
2475166	RxNorm	Voclosporin	
<b>Vosoritide</b>			
2586354	RxNorm	Vosoritide	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Network:</b>	
USA Minimal Shift network	
<b>2021 Strata</b>	
<b>Cohort 1: Aducanumab-avwa</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Aducanumab-avwa	December 18, 2020 - December 17, 2021
<b>Cohort 2: Amivantamab-vmjw</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Amivantamab-vmjw	December 18, 2020 - December 17, 2021
<b>Cohort 3: Anifrolumab-fnia</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Anifrolumab-fnia	December 18, 2020 - December 17, 2021
<b>Cohort 4: Asciminib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asciminib	December 18, 2020 - December 17, 2021
<b>Cohort 5: Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 6: Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn	December 18, 2020 - December 17, 2021
[FILTER]: Brand name = Rylaze	
<b>Cohort 7: Atogepant</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Atogepant	December 18, 2020 - December 17, 2021
<b>Cohort 8: Avacopan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avacopan	December 18, 2020 - December 17, 2021
<b>Cohort 9: Avalglucosidase Alfa-ngpt</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avalglucosidase Alfa-ngpt	December 18, 2020 - December 17, 2021
<b>Cohort 10: Belumosudil</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belumosudil	December 18, 2020 - December 17, 2021
<b>Cohort 11: Belzutifan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belzutifan	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 12: Cabotegravir (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - December 17, 2021
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 13: Cabotegravir (Route: Oral)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - December 17, 2021
<i>[FILTER]: Route = Oral</i>	
<b>Cohort 14: Cabotegravir (Route: Injectable)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - December 17, 2021
<i>[FILTER]: Route = Injectable</i>	
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 15: Cabotegravir (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - December 17, 2021
<i>[FILTER]: Brand = Apretude or Vocabria</i>	



**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 16: Cabotegravir and Rilpivirine (Route: Injectable)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - December 17, 2021
[FILTER]: Route = Injectable	
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
[FILTER]: Route = Injectable	
<b>Cohort 17: Casimersen</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Casimersen	December 18, 2020 - December 17, 2021
<b>Cohort 18: Dasiglucagon</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dasiglucagon	December 18, 2020 - December 17, 2021
<b>Cohort 19: Difelikefalin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Difelikefalin	December 18, 2020 - December 17, 2021
<b>Cohort 20: Dostarlimab-gxly</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dostarlimab-gxly	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 21: Drospirenone and Estetrol</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Drospirenone	December 18, 2020 - December 17, 2021
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Estetrol	On the same day as subgroup 1A (drospirenone)
<b>Cohort 22: Efgartigimod Alfa-fcab (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod Alfa-fcab	December 18, 2020 - December 17, 2021
<b>Cohort 23: Efgartigimod Alfa-fcab (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod Alfa-fcab	December 18, 2020 - December 17, 2021
[FILTER]: Brand name = Vyvgart	
<b>Cohort 24: Evinacumab-dgnb</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Evinacumab-dgnb	December 18, 2020 - December 17, 2021
<b>Cohort 25: Fexinidazole</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Fexinidazole	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 26: Finerenone</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Finerenone	December 18, 2020 - December 17, 2021
<b>Cohort 27: Fosdenopterin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Fosdenopterin	December 18, 2020 - December 17, 2021
<b>Cohort 28: Ibrexafungerp</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ibrexafungerp	December 18, 2020 - December 17, 2021
<b>Cohort 29: Inclisiran</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Inclisiran	December 18, 2020 - December 17, 2021
<b>Cohort 30: Infigratinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Infigratinib	December 18, 2020 - December 17, 2021
<b>Cohort 31: Loncastuximab Tesirine-lpyl</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Loncastuximab Tesirine-lpyl	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 32: Lonapegsomatropin-tcgd</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Lonapegsomatropin-tcgd	December 18, 2020 - December 17, 2021
<b>Cohort 33: Maralixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maralixibat	December 18, 2020 - December 17, 2021
<b>Cohort 34: Maribavir</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maribavir	December 18, 2020 - December 17, 2021
<b>Cohort 35: Melphalan Flufenamide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Melphalan Flufenamide	December 18, 2020 - December 17, 2021
<b>Cohort 36: Mobocertinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Mobocertinib	December 18, 2020 - December 17, 2021
<b>Cohort 37: Odevixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Odevixibat	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 38: Olanzapine and Samidorphan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Olanzapine	December 18, 2020 - December 17, 2021
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Samidorphan	On the same day as subgroup 1A (olanzapine)
<b>Cohort 39: Pafolacianine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pafolacianine	December 18, 2020 - December 17, 2021
<b>Cohort 40: Pegcetacoplan (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2020 - December 17, 2021
<b>Cohort 41: Pegcetacoplan (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2020 - December 17, 2021
<i>[FILTER]: Brand = Empaveli</i>	
<b>Cohort 42: Piflufolastat F-18</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Piflufolastat F-18	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 43: Ponesimod</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ponesimod	December 18, 2020 - December 17, 2021
<b>Cohort 44: Ropeginterferon Alfa-2b-njft</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ropeginterferon Alfa-2b-njft	December 18, 2020 - December 17, 2021
<b>Cohort 45: Serdexmethylphenidate and Dexmethylphenidate</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Serdexmethylphenidate	December 18, 2020 - December 17, 2021
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Dexmethylphenidate	On the same day as subgroup 1A (Serdexmethylphenidate)
<b>Cohort 46: Sotorasib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Sotorasib	December 18, 2020 - December 17, 2021
<b>Cohort 47: Tepotinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tepotinib	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 48: Tezepelumab-ekko</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tezepelumab-ekko	December 18, 2020 - December 17, 2021
<b>Cohort 49: Tisotumab Vedotin-tftv</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tisotumab Vedotin-tftv	December 18, 2020 - December 17, 2021
<b>Cohort 50: Tivozanib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tivozanib	December 18, 2020 - December 17, 2021
<b>Cohort 51: Tralokinumab-ldrm</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tralokinumab-ldrm	December 18, 2020 - December 17, 2021
<b>Cohort 52: Trilaciclib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Trilaciclib	December 18, 2020 - December 17, 2021
<b>Cohort 53: Umbralisib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Umbralisib	December 18, 2020 - December 17, 2021

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 54: Vericiguat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vericiguat	December 18, 2020 - December 17, 2021
<b>Cohort 55: Viloxazine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Viloxazine	December 18, 2020 - December 17, 2021
<b>Cohort 56: Voclosporin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Voclosporin	December 18, 2020 - December 17, 2021
<b>Cohort 57: Vosoritide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vosoritide	December 18, 2020 - December 17, 2021



**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Network:</b>	
USA Minimal Shift network	
<b>2022 Strata</b>	
<b>Cohort 58: Aducanumab-avwa</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Aducanumab-avwa	December 18, 2021 - December 17, 2022
<b>Cohort 59: Amivantamab-vmjw</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Amivantamab-vmjw	December 18, 2021 - December 17, 2022
<b>Cohort 60: Anifrolumab-fnia</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Anifrolumab-fnia	December 18, 2021 - December 17, 2022
<b>Cohort 61: Asciminib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asciminib	December 18, 2021 - December 17, 2022
<b>Cohort 62: Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 63: Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn	December 18, 2021 - December 17, 2022
[FILTER]: Brand name = Rylaze	
<b>Cohort 64: Atogepant</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Atogepant	December 18, 2021 - December 17, 2022
<b>Cohort 65: Avacopan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avacopan	December 18, 2021 - December 17, 2022
<b>Cohort 66: Avalglucosidase Alfa-ngpt</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avalglucosidase Alfa-ngpt	December 18, 2021 - December 17, 2022
<b>Cohort 67: Belumosudil</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belumosudil	December 18, 2021 - December 17, 2022
<b>Cohort 68: Belzutifan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belzutifan	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 69: Cabotegravir (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2021 - December 17, 2022
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 70: Cabotegravir (Route: Oral)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2021 - December 17, 2022
<i>[FILTER]: Route = Oral</i>	
<b>Cohort 71: Cabotegravir (Route: Injectable)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2021 - December 17, 2022
<i>[FILTER]: Route = Injectable</i>	
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 72: Cabotegravir (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2021 - December 17, 2022
<i>[FILTER]: Brand = Apretude or Vocabria</i>	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 73: Cabotegravir and Rilpivirine (Route: Injectable)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2021 - December 17, 2022
[FILTER]: Route = Injectable	
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
[FILTER]: Route = Injectable	
<b>Cohort 74: Casimersen</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Casimersen	December 18, 2021 - December 17, 2022
<b>Cohort 75: Dasiglucagon</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dasiglucagon	December 18, 2021 - December 17, 2022
<b>Cohort 76: Difelikefalin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Difelikefalin	December 18, 2021 - December 17, 2022
<b>Cohort 77: Dostarlimab-gxly</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dostarlimab-gxly	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 78: Drospirenone and Estetrol</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Drospirenone	December 18, 2021 - December 17, 2022
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Estetrol	On the same day as subgroup 1A (drospirenone)
<b>Cohort 79: Efgartigimod Alfa-fcab (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod Alfa-fcab	December 18, 2021 - December 17, 2022
<b>Cohort 80: Efgartigimod Alfa-fcab (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod Alfa-fcab	December 18, 2021 - December 17, 2022
[FILTER]: Brand name = Vyvgart	
<b>Cohort 81: Evinacumab-dgnb</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Evinacumab-dgnb	December 18, 2021 - December 17, 2022
<b>Cohort 82: Fexinidazole</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Fexinidazole	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 83: Finerenone</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Finerenone	December 18, 2021 - December 17, 2022
<b>Cohort 84: Fosdenopterin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Fosdenopterin	December 18, 2021 - December 17, 2022
<b>Cohort 85: Ibrexafungerp</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ibrexafungerp	December 18, 2021 - December 17, 2022
<b>Cohort 86: Inclisiran</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Inclisiran	December 18, 2021 - December 17, 2022
<b>Cohort 87: Infigratinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Infigratinib	December 18, 2021 - December 17, 2022
<b>Cohort 88: Loncastuximab Tesirine-lpyl</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Loncastuximab Tesirine-lpyl	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 89: Lonapegsomatropin-tcgd</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Lonapegsomatropin-tcgd	December 18, 2021 - December 17, 2022
<b>Cohort 90: Maralixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maralixibat	December 18, 2021 - December 17, 2022
<b>Cohort 91: Maribavir</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maribavir	December 18, 2021 - December 17, 2022
<b>Cohort 92: Melphalan Flufenamide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Melphalan Flufenamide	December 18, 2021 - December 17, 2022
<b>Cohort 93: Mobocertinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Mobocertinib	December 18, 2021 - December 17, 2022
<b>Cohort 94: Odevixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Odevixibat	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 95: Olanzapine and Samidorphan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Olanzapine	December 18, 2021 - December 17, 2022
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Samidorphan	On the same day as subgroup 1A (olanzapine)
<b>Cohort 96: Pafolacianine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pafolacianine	December 18, 2021 - December 17, 2022
<b>Cohort 97: Pegcetacoplan (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2021 - December 17, 2022
<b>Cohort 98: Pegcetacoplan (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2021 - December 17, 2022
<i>[FILTER]: Brand = Empaveli</i>	
<b>Cohort 99: Piflufolastat F-18</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Piflufolastat F-18	December 18, 2021 - December 17, 2022



**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 100: Ponesimod</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ponesimod	December 18, 2021 - December 17, 2022
<b>Cohort 101: Ropeginterferon Alfa-2b-njft</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ropeginterferon Alfa-2b-njft	December 18, 2021 - December 17, 2022
<b>Cohort 102: Serdexmethylphenidate and Dexmethylphenidate</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Serdexmethylphenidate	December 18, 2021 - December 17, 2022
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Dexmethylphenidate	On the same day as subgroup 1A (Serdexmethylphenidate)
<b>Cohort 103: Sotorasib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Sotorasib	December 18, 2021 - December 17, 2022
<b>Cohort 104: Tepotinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tepotinib	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 105: Tezepelumab-ekko</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tezepelumab-ekko	December 18, 2021 - December 17, 2022
<b>Cohort 106: Tisotumab Vedotin-tftv</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tisotumab Vedotin-tftv	December 18, 2021 - December 17, 2022
<b>Cohort 107: Tivozanib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tivozanib	December 18, 2021 - December 17, 2022
<b>Cohort 108: Tralokinumab-ldrm</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tralokinumab-ldrm	December 18, 2021 - December 17, 2022
<b>Cohort 109: Trilaciclib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Trilaciclib	December 18, 2021 - December 17, 2022
<b>Cohort 110: Umbralisib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Umbralisib	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 111: Vericiguat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vericiguat	December 18, 2021 - December 17, 2022
<b>Cohort 112: Viloxazine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Viloxazine	December 18, 2021 - December 17, 2022
<b>Cohort 113: Voclosporin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Voclosporin	December 18, 2021 - December 17, 2022
<b>Cohort 114: Vosoritide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vosoritide	December 18, 2021 - December 17, 2022

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Network:</b>	
USA Minimal Shift network	
<b>2023 Strata</b>	
<b>Cohort 115: Aducanumab-avwa</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Aducanumab-avwa	December 18, 2022 - December 31, 2023
<b>Cohort 116: Amivantamab-vmjw</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Amivantamab-vmjw	December 18, 2022 - December 31, 2023
<b>Cohort 117: Anifrolumab-fnia</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Anifrolumab-fnia	December 18, 2022 - December 31, 2023
<b>Cohort 118: Asciminib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asciminib	December 18, 2022 - December 31, 2023
<b>Cohort 119: Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 120: Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn	December 18, 2022 - December 31, 2023
[FILTER]: Brand name = Rylaze	
<b>Cohort 121: Atogepant</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Atogepant	December 18, 2022 - December 31, 2023
<b>Cohort 122: Avacopan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avacopan	December 18, 2022 - December 31, 2023
<b>Cohort 123: Avalglucosidase Alfa-ngpt</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avalglucosidase Alfa-ngpt	December 18, 2022 - December 31, 2023
<b>Cohort 124: Belumosudil</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belumosudil	December 18, 2022 - December 31, 2023
<b>Cohort 125: Belzutifan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belzutifan	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 126: Cabotegravir (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2022 - December 31, 2023
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 127: Cabotegravir (Route: Oral)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2022 - December 31, 2023
<i>[FILTER]: Route = Oral</i>	
<b>Cohort 128: Cabotegravir (Route: Injectable)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2022 - December 31, 2023
<i>[FILTER]: Route = Injectable</i>	
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 129: Cabotegravir (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2022 - December 31, 2023
<i>[FILTER]: Brand = Apretude or Vocabria</i>	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 130: Cabotegravir and Rilpivirine (Route: Injectable)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2022 - December 31, 2023
[FILTER]: Route = Injectable	
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
[FILTER]: Route = Injectable	
<b>Cohort 131: Casimersen</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Casimersen	December 18, 2022 - December 31, 2023
<b>Cohort 132: Dasiglucagon</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dasiglucagon	December 18, 2022 - December 31, 2023
<b>Cohort 133: Difelikefalin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Difelikefalin	December 18, 2022 - December 31, 2023
<b>Cohort 134: Dostarlimab-gxly</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dostarlimab-gxly	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 135: Drospirenone and Estetrol</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Drospirenone	December 18, 2022 - December 31, 2023
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Estetrol	On the same day as subgroup 1A (drospirenone)
<b>Cohort 136: Efgartigimod Alfa-fcab (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod Alfa-fcab	December 18, 2022 - December 31, 2023
<b>Cohort 137: Efgartigimod Alfa-fcab (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod Alfa-fcab	December 18, 2022 - December 31, 2023
[FILTER]: Brand name = Vyvgart	
<b>Cohort 138: Evinacumab-dgnb</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Evinacumab-dgnb	December 18, 2022 - December 31, 2023
<b>Cohort 139: Fexinidazole</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Fexinidazole	December 18, 2022 - December 31, 2023



**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 140: Finerenone</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Finerenone	December 18, 2022 - December 31, 2023
<b>Cohort 141: Fosdenopterin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Fosdenopterin	December 18, 2022 - December 31, 2023
<b>Cohort 142: Ibrexafungerp</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ibrexafungerp	December 18, 2022 - December 31, 2023
<b>Cohort 143: Inclisiran</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Inclisiran	December 18, 2022 - December 31, 2023
<b>Cohort 144: Infigratinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Infigratinib	December 18, 2022 - December 31, 2023
<b>Cohort 145: Loncastuximab Tesirine-lpyl</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Loncastuximab Tesirine-lpyl	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 146: Lonapegsomatropin-tcgd</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Lonapegsomatropin-tcgd	December 18, 2022 - December 31, 2023
<b>Cohort 147: Maralixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maralixibat	December 18, 2022 - December 31, 2023
<b>Cohort 148: Maribavir</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maribavir	December 18, 2022 - December 31, 2023
<b>Cohort 149: Melphalan Flufenamide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Melphalan Flufenamide	December 18, 2022 - December 31, 2023
<b>Cohort 150: Mobocertinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Mobocertinib	December 18, 2022 - December 31, 2023
<b>Cohort 151: Odevixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Odevixibat	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 152: Olanzapine and Samidorphan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Olanzapine	December 18, 2022 - December 31, 2023
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Samidorphan	On the same day as subgroup 1A (olanzapine)
<b>Cohort 153: Pafolacianine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pafolacianine	December 18, 2022 - December 31, 2023
<b>Cohort 154: Pegcetacoplan (Overall, Filter: None)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2022 - December 31, 2023
<b>Cohort 155: Pegcetacoplan (Filter: Brand)</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2022 - December 31, 2023
<i>[FILTER]: Brand = Empaveli</i>	
<b>Cohort 156: Piflufolastat F-18</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Piflufolastat F-18	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 157: Ponesimod</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ponesimod	December 18, 2022 - December 31, 2023
<b>Cohort 158: Ropeginterferon Alfa-2b-njft</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ropeginterferon Alfa-2b-njft	December 18, 2022 - December 31, 2023
<b>Cohort 159: Serdexmethylphenidate and Dexmethylphenidate</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Serdexmethylphenidate	December 18, 2022 - December 31, 2023
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Dexmethylphenidate	On the same day as subgroup 1A (Serdexmethylphenidate)
<b>Cohort 160: Sotorasib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Sotorasib	December 18, 2022 - December 31, 2023
<b>Cohort 161: Tepotinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tepotinib	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 162: Tezepelumab-ekko</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tezepelumab-ekko	December 18, 2022 - December 31, 2023
<b>Cohort 163: Tisotumab Vedotin-tftv</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tisotumab Vedotin-tftv	December 18, 2022 - December 31, 2023
<b>Cohort 164: Tivozanib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tivozanib	December 18, 2022 - December 31, 2023
<b>Cohort 165: Tralokinumab-ldrm</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tralokinumab-ldrm	December 18, 2022 - December 31, 2023
<b>Cohort 166: Trilaciclib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Trilaciclib	December 18, 2022 - December 31, 2023
<b>Cohort 167: Umbralisib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Umbralisib	December 18, 2022 - December 31, 2023

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 168: Vericiguat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vericiguat	December 18, 2022 - December 31, 2023
<b>Cohort 169: Viloxazine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Viloxazine	December 18, 2022 - December 31, 2023
<b>Cohort 170: Voclosporin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Voclosporin	December 18, 2022 - December 31, 2023
<b>Cohort 171: Vosoritide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vosoritide	December 18, 2022 - December 31, 2023